Guangzhou Lupeng/Newave Pharmaceutical Inc. Enrolled the First Patient in the Global Phase 3 ROCKET-CLL Trial Evaluating Rocbrutinib (LP-168) vs. Pirtobrutinib in R/R CLL/SLL
Head-to-Head Study Highlights Rocbrutinib as the World's First Fourth-Generation Dual Covalent and Non-Covalent BTK Inhibitor Designed to Overcome Resistance Mutations GUANGZHOU, China and SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Lupeng...
SeABank reports profit before tax of US$168.14 million in Q1/2025
HANOI, Vietnam, April 17, 2025 /PRNewswire/ -- Southeast Asia Commercial Joint Stock Bank (SeABank, stock code: SSB) announced its consolidated first-quarter results 2025 with positive figures, reflecting robust performance. SeABank reports profit...
The World's First 660 MW Ultra-Supercritical CFB Power Project Commences Operations
BINCHANG, China, Dec. 13, 2024 /PRNewswire/ -- Developed by Harbin Electric Corporation, the world's first 660 MW high-efficiency ultra-supercritical circulating fluidized bed (CFB) power generation unit, featuring the highest specifications and...